ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2017
The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries.
Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Clustering on longitudinal quality-of-life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial.Cancer medicine · 2023Trial
- The PICO Puzzle: Can Public Data Predict EU HTA Expectations for All EU Countries?Journal of market access & health policy · 2025Article
- Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastaticThe Lancet regional health. Western Pacific · 2024Article
- Assessment of quality of data submitted for NICE technology appraisals over two decades.BMJ open · 2024Article
- Patient preferences do matter: a discrete choice experiment conducted with breast cancer patients in six European countries, with latent class analysis.International journal of technology assessment in health care · 2023Article
- Nutrition care is an integral part of patient-centred medical care: a European consensus.Medical oncology (Northwood, London, England) · 2023Article
- Patient-Reported Outcomes (PROs) in HIV Infection: Points to Consider and Challenges.Infectious diseases and therapy · 2022Article
- Consideration of quality of life in the health technology assessments of rare disease treatments.The European journal of health economics : HEPAC : health economics in prevention and care · 2022Article
- Patient Selection for Local Aggressive Treatment in Oligometastatic Non-Small Cell Lung Cancer.Cancers · 2021Review
- Information Patients With Melanoma Spontaneously Report About Health-Related Quality of Life on Web-Based Forums: Case Study.Journal of medical Internet research · 2021Article
- Psychosocial aspects and life project disruption in young women diagnosed with metastatic hormone-sensitive HER2-negative breast cancer.Breast (Edinburgh, Scotland) · 2020Review
- Anti-cervical cancer activity of secondary metabolites of endophytic fungi from Ginkgo biloba.Cancer biomarkers : section A of Disease markers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study is to investigate the role of health-related quality-of-life (QoL) data in relative effectiveness assessments (REAs) of new anti-cancer drugs across European jurisdictions, during health technology assessment procedures.
methodsComparative analysis of guidelines and publicly available REAs in six European jurisdictions of anti-cancer drugs approved by EMA between 2011 and 2013.
resultsFourteen anti-cancer drugs were included, adding up to 79 REAs. Whilst all guidelines state that QoL is a relevant endpoint to determine the relative effectiveness of new cancer drugs, QoL data were included in only 54% of the 79 reports and their impact on the recommendations was limited.
conclusionsWhilst national guidelines recognize the relevance of QoL to determine the relative effectiveness of new anti-cancer drugs, this is not well-reflected in current assessments. Developing and implementing into REAs specific evidence requirements for QoL data would improve the use of this patient-centred outcome in future reimbursement and pricing decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.